目的 觀察通心絡(luò)膠囊聯(lián)合福辛普利治療缺血性心肌病的臨床療效。方法 選取2015年1月—2017年1月在青島思達(dá)心臟醫(yī)院就診的缺血性心肌病患者82例，隨機(jī)分為對照組和治療組，每組各41例。對照組口服福辛普利鈉片，10 mg/次，1次/d；治療組在對照組的基礎(chǔ)上口服通心絡(luò)膠囊，2～4粒/次，3次/d。兩組患者均治療2周。觀察兩組患者臨床療效和心電圖療效，同時比較治療前后兩組患者靜息心率、收縮壓、舒張壓、三酰甘油（TG）、總膽固醇（CHO）、低密度脂蛋白（LDL-C）、N末端B型鈉尿肽原（NT-proBNP）、左心室舒張末期內(nèi)徑（LVEDD）、左心室收縮末期內(nèi)徑（LVESD）和左室射血分?jǐn)?shù)（LVEF）。結(jié)果 治療后，對照組臨床有效率和心電圖療效分別為73.17%和68.29%，均分別顯著低于治療組90.24%和87.80%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者靜息心率、收縮壓和舒張壓均顯著降低（P<0.05），且治療組靜息心率、收縮壓和舒張壓水平明顯低于對照組（P<0.05）。治療后，兩組TG、CHO、LDL-C和NT-proBNP水平均顯著降低（P<0.05），且治療組TG、CHO、LDL-C和NT-proBNP水平明顯低于對照組（P<0.05）。治療后，兩組LVEDD和LVESD顯著降低（P<0.05），LVEF顯著升高（P<0.05），且治療組患者心功能明顯好于對照組（P<0.05）。結(jié)論 通心絡(luò)膠囊聯(lián)合福辛普利治療缺血性心肌病，能有效改善患者的臨床癥狀、炎性反應(yīng)和血脂水平。

Objective To observe the clinical effect of Tongxinluo Capsules combined with fosinopril in treatment of ischemic cardiomyopathy. Methods Patients (82 cases) with ischemic cardiomyopathy in Qingdao Starr Heart Hospital from January 2015 to January 2017 were randomly divided into control and treatment groups, and each group had 41 cases. Patients in the control group were po administered with Fosinopril Sodium Tablets, 10 mg/time, once daily. Patients in the treatment group were po administered with Tongxinluo Capsules on the basis of the control group, 2 - 4 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical and electrocardiogram efficacy were evaluated, and the resting heart rate, systolic and diastolic blood pressure, TG, CHO, LDL-C, NT-proBNP, LVEDD, LVESD and LVEF in two groups before and after treatment were compared. Results After treatment, the clinical and electrocardiogram efficacy in the control group were 73.17% and 68.29%, which were significantly lower than 90.24% and 87.80% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the resting heart rate, systolic and diastolic blood pressure in two groups were significantly decreased (P<0.05), which in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the ITG, CHO, LDL-C and NT-proBNP levels in two groups were significantly decreased (P<0.05), and these indicators in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the LVEDD and LVESD in two groups were significantly decreased (P<0.05), but LVEF was significantly increased (P<0.05), and the cardiac function indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Tongxinluo Capsules combined with fosinopril in treatment of ischemic cardiomyopathy can effectively improve the clinical symptoms, the inflammatory response and blood lipid levels.